Skip to main content

Advertisement

Table 1 Correlation between miR-29c expression and different clinical characteristics

From: MicroRNA-29c functions as a tumor suppressor by targeting VEGFA in lung adenocarcinoma

  Patients with low miR-29c expression Patients with high miR-29c expression p
Age    0.165
  < 60 y 27 (61.4%) 20 (46.5%)  
  ≥ 60 y 17 (38.6%) 23 (53.3%)  
Sex    0.458
 Male 27 (61.4%) 23 (53.5%)  
 Female 17 (38.6%) 20 (46.5%)  
ECOG performance status    0.740
 0 21 (47.7%) 19 (44.2%)  
 1 23 (52.3%) 24 (55.8%)  
Weight loss    1.000
  ≤ 5% 42 (95.5%) 41 (95.3%)  
  > 5% 2 (4.5%) 2 (4.7%)  
Smoking status    0.137
 Smokers 19 (43.2%) 12 (27.9%)  
 Nonsmokers 25 (56.8%) 31 (72.1%)  
Tumor stage    0.324
 1 3 (6.8%) 7 (16.3%)  
 2 32 (72.7%) 30 (69.8%)  
 3 9 (20.5%) 6 (14.0%)  
Postoperative chemotherapy    0.313
 Yes 40 (90.9%) 36 (83.7%)  
 No 4 (9.1%) 7 (16.3%)  
Postoperative radiotherapy    0.125
 Yes 12 (27.3%) 6 (14.0%)  
 No 32 (72.7%) 37 (86.0%)